C5 and paroxysmal nocturnal hemoglobinuria: The incidence of thrombosis in PNH patients has decreased considerably since the introduction of complement 5 (C5) inhibitors (e.g., eculizumab, ravulizumab), but the risk is not eliminated completely [4,5,6].